Temsamani F, Agalit A, Idrissi Serhrouchni K
Cureus. 2025; 17(1):e77362.
PMID: 39944459
PMC: 11815987.
DOI: 10.7759/cureus.77362.
Xiang Z, Ye Q, Zhao Z, Wang N, Li J, Zou M
Mol Genet Genomics. 2024; 299(1):74.
PMID: 39085666
DOI: 10.1007/s00438-024-02167-w.
Vo Q, Saito Y, Ida T, Nakamura K, Yuasa S
PLoS One. 2024; 19(5):e0302537.
PMID: 38771829
PMC: 11108174.
DOI: 10.1371/journal.pone.0302537.
Swaidan N, Soliman N, Aboughalia A, Darwish T, Almeshal R, Al-Khulaifi A
Front Mol Biosci. 2024; 11:1342011.
PMID: 38375508
PMC: 10875024.
DOI: 10.3389/fmolb.2024.1342011.
Babini H, Jimenez-Sabado V, Stogova E, Arslanova A, Butt M, Dababneh S
Front Cell Dev Biol. 2024; 12:1298007.
PMID: 38304423
PMC: 10830749.
DOI: 10.3389/fcell.2024.1298007.
The Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics.
Mehra V, Chhetri J, Ali S, Roddie C
Biology (Basel). 2023; 12(11).
PMID: 37998018
PMC: 10669440.
DOI: 10.3390/biology12111419.
Potential Therapeutic Use of Stem Cells for Prion Diseases.
Zayed M, Kook S, Jeong B
Cells. 2023; 12(19).
PMID: 37830627
PMC: 10571911.
DOI: 10.3390/cells12192413.
A rational consideration of the genomic instability of human-induced pluripotent stem cells for clinical applications.
Zhang H, Jin Z
Sci China Life Sci. 2023; 66(9):2198-2200.
PMID: 37296348
DOI: 10.1007/s11427-023-2354-6.
Characterization of human induced pluripotent stems cells: Current approaches, challenges, and future solutions.
Babu S, Duvvuru H, Baker J, Switalski S, Shafa M, Panchalingam K
Biotechnol Rep (Amst). 2023; 37:e00784.
PMID: 36818379
PMC: 9929203.
DOI: 10.1016/j.btre.2023.e00784.
Natural killer cells in clinical development as non-engineered, engineered, and combination therapies.
Lamers-Kok N, Panella D, Georgoudaki A, Liu H, Ozkazanc D, Kucerova L
J Hematol Oncol. 2022; 15(1):164.
PMID: 36348457
PMC: 9644572.
DOI: 10.1186/s13045-022-01382-5.
Standardization of Cell Culture Conditions and Routine Genomic Screening under a Quality Management System Leads to Reduced Genomic Instability in hPSCs.
Molina-Ruiz F, Introna C, Bombau G, Galofre M, Canals J
Cells. 2022; 11(13).
PMID: 35805069
PMC: 9265327.
DOI: 10.3390/cells11131984.
Moving Towards Induced Pluripotent Stem Cell-based Therapies with Artificial Intelligence and Machine Learning.
Coronnello C, Francipane M
Stem Cell Rev Rep. 2021; 18(2):559-569.
PMID: 34843066
PMC: 8930923.
DOI: 10.1007/s12015-021-10302-y.
Developing standards to support the clinical translation of stem cells.
Cao J, Hao J, Wang L, Tan Y, Tian Y, Li S
Stem Cells Transl Med. 2021; 10 Suppl 2:S85-S95.
PMID: 34724717
PMC: 8560191.
DOI: 10.1002/sct3.13035.
Oxygen as a Master Regulator of Human Pluripotent Stem Cell Function and Metabolism.
Nit K, Tyszka-Czochara M, Bobis-Wozowicz S
J Pers Med. 2021; 11(9).
PMID: 34575682
PMC: 8466012.
DOI: 10.3390/jpm11090905.
L- Gene Expression in Canine Fetal Fibroblasts Promotes Self-Renewal Capacity but Not Tumor Formation.
Kim S, Kim B, Kim J, Kim D, Lee S, Lee D
Cells. 2021; 10(8).
PMID: 34440750
PMC: 8391401.
DOI: 10.3390/cells10081980.
Contiguous erosion of the inactive X in human pluripotency concludes with global DNA hypomethylation.
Bansal P, Ahern D, Kondaveeti Y, Qiu C, Pinter S
Cell Rep. 2021; 35(10):109215.
PMID: 34107261
PMC: 8267460.
DOI: 10.1016/j.celrep.2021.109215.
Hematopoietic stem cell- and induced pluripotent stem cell-derived CAR-NK cells as reliable cell-based therapy solutions.
Arias J, Yu J, Varshney M, Inzunza J, Nalvarte I
Stem Cells Transl Med. 2021; 10(7):987-995.
PMID: 33634954
PMC: 8235144.
DOI: 10.1002/sctm.20-0459.
Great Expectations: Induced pluripotent stem cell technologies in neurodevelopmental impairments.
Zhang X, Li Z, Liu Y, Gai Z
Int J Med Sci. 2021; 18(2):459-473.
PMID: 33390815
PMC: 7757149.
DOI: 10.7150/ijms.51842.
A Human Induced Pluripotent Stem Cell-Derived Isogenic Model of Huntington's Disease Based on Neuronal Cells Has Several Relevant Phenotypic Abnormalities.
Malankhanova T, Suldina L, Grigoreva E, Medvedev S, Minina J, Morozova K
J Pers Med. 2020; 10(4).
PMID: 33182269
PMC: 7712151.
DOI: 10.3390/jpm10040215.
Precise Correction of Heterozygous SHOX2 Mutations in hiPSCs Derived from Patients with Atrial Fibrillation via Genome Editing and Sib Selection.
Sumer S, Hoffmann S, Laue S, Campbell B, Raedecke K, Frajs V
Stem Cell Reports. 2020; 15(4):999-1013.
PMID: 32976766
PMC: 7562944.
DOI: 10.1016/j.stemcr.2020.08.015.